Risk profiling for cirrhosis and hepatocellular carcinoma in HFE hemochromatosis using mobilizable iron stores and

Natasha D P Mitchell1, Timothy G St Pierre2, Louise E Ramm3,4

  • 1Department of Gastroenterology, Fiona Stanley Hospital, Murdoch, WA, Australia.

Scientific Reports
|May 9, 2025
PubMed

Insights

HFE hemochromatosis (HH) patients with high iron stores and alcohol consumption face increased cirrhosis risk. Early assessment of these factors can predict future liver cancer (HCC) development in HH.

Area of Science:

  • Hepatology
  • Genetics
  • Oncology

Background:

  • HFE hemochromatosis (HH) is a genetic disorder causing excessive iron absorption.
  • Iron overload in HH can lead to liver cirrhosis and hepatocellular carcinoma (HCC).
  • Alcohol consumption is a known cofactor exacerbating liver damage in HH.

Purpose of the Study:

  • To evaluate alcohol and iron-related risk factors for cirrhosis at diagnosis and HCC development in HH patients.
  • To develop a predictive model for cirrhosis and assess future HCC risk based on identified factors.

Main Methods:

  • Retrospective analysis of 197 HH subjects.
  • Logistic regression modeling incorporating mobilizable iron stores, alcohol consumption, and age.
  • Area Under the Receiver Operating Characteristic Curve (AUROC) analysis for model validation.

Main Results:

  • The study identified a significant association between iron overload, alcohol consumption, and cirrhosis risk.
  • The developed logistic regression model demonstrated high accuracy (AUROC 0.966) in predicting cirrhosis.
  • The model showed a high negative predictive value (99.4%) for future HCC development.

Conclusions:

  • Mobilizable iron stores and alcohol consumption are key predictors of cirrhosis in HH.
  • These factors can be used to assess the future risk of HCC in HH patients.
  • Early identification and management of these risk factors are crucial for preventing severe liver outcomes.

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
Cirrhosis I: Introduction01:23

Cirrhosis I: Introduction

Cirrhosis is a chronic, irreversible liver disease characterized by the widespread replacement of healthy liver tissue with fibrotic scar tissue and the formation of regenerative nodules.Etiology of cirrhosisCirrhosis results from sustained liver injury that triggers progressive fibrosis and structural remodeling. The underlying causes are diverse, encompassing common and less frequent clinical conditions. Regardless of the origin, all causes lead to chronic inflammation, hepatocyte loss, and...
Cirrhosis II: Pathophysiology01:24

Cirrhosis II: Pathophysiology

Cirrhosis is a progressive chronic liver injury caused by prolonged inflammation, excessive fibrotic remodeling, and impaired regeneration. Over time, repeated hepatic insults disrupt the liver’s architecture and function, leading to reduced blood flow, impaired bile drainage, and diminished metabolic capacity.Pathophysiology of cirrhosisCirrhosis arises from three main responses to chronic liver damage: inflammation, immune activation, and hepatocyte death. These processes lead to structural...